Mitobridge

12 articles about Mitobridge

• Generian Achieves First Milestones in Mitobridge Collaboration

  2/8/2023

  Generian Pharmaceuticals, Inc. announced that it has achieved the first research milestones for two programs in development under its collaboration agreement with Mitobridge, Inc.

• OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company

  11/2/2022

  OrsoBio, Inc. today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.

• Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets

  6/29/2022

  Generian Pharmaceuticals, Inc. ("Generian") and Mitobridge, Inc.  (a wholly owned subsidiary of Astellas Pharma Inc. ) announced today that they have entered into a collaboration and exclusive license agreement to discover and develop novel small molecules for undruggable therapeutic targets by using a proprietary drug discovery platform for diseases that have limited treatment options.

• 

  Astellas Pushes Outside of Oncology, Releases Positive Results in Anemia Trials

  9/21/2018

  Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.

• Astellas Completes Acquisition of Mitobridge

  1/24/2018

  By exercising the option right to acquire Mitobridge, Astellas paid $225M to acquire 100% of the equity in Mitobridge.

• 

  Gilead Doubles Down on CAR-T

  12/12/2017

  Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its "Throttle" technology.
• 

  Astellas Takes Out Massachusetts' Biotech Mitobridge in $390M Deal

  12/1/2017

  Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013.

• Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARδ Modulators in Acute Kidney Injury at American Society of Nephrology Annual Meeting

  11/6/2017

  The data demonstrated that Mitobridge’s proprietary compound MA-0217 corrects the mitochondrial deficits and alleviates the renal dysfunction in a rat ischemia reperfusion AKI model.

• Meet the Scientist Who's Obsessed With Discovering an Exercise Pill That Won't Give You Cancer

  10/17/2017

  Ronald Evans believes he’s much closer to a fat-burning, muscle-growing drug that won’t, uh, give you cancer.

• Mitobridge Adds NAD+ Modulation As A Therapeutic Approach For Improving Mitochondrial Function

  9/18/2017

• Mitobridge’s Novel Treatment Approach For Duchenne Muscular Dystrophy Advances Into Clinical Development

  8/8/2017

• Mitobridge’s Novel Treatment Approach For Duchenne Muscular Dystrophy Advances Into Clinical Development

  8/8/2017